By Richard Staines, Optimum Strategic Communications As the Optimum team prepares for its 16th Annual Healthcare Investor Conference on Thursday, the mood is upbeat in the biopharma finance market, with 2024 turning into a busy year. It’s a turnaround following 2023, where investment was in the doldrums and confidence was low as the industry suffered […]
LONDON, Oct. 8, 2024 /PRNewswire/ — Optimum Strategic Communications (Optimum), the international strategic healthcare communications consultancy, will be hosting its 16th Annual Healthcare Investor Conference on Thursday 10 October, 2024 at The Kings Fund, London. This year, as markets begin to bounce back after a lacklustre period, a prestigious line-up of industry experts will look to growth, identifying which therapies will attract investor […]
Optimum’s annual conference brings together top executives and business leaders from the life sciences and investment communities. As well as a series of star-studded panels, this year will see the introduction of a “Speed Dating” service where biotechs get a chance to meet with some of the most influential investors in the industry. The event […]
A multi-billion dollar collaboration between Prime Medicine Inc. and Bristol-Myers Squibb brings this important technology closer to patients. At the end of 2023, the FDA already approved Casgevy (exagamglogene autotemcel), developed jointly by CRISPR Therapeutics and Vertex Pharmaceuticals for sickle cell disease and beta thalassemia, and bluebird bio’s Lyfgenia (lovotibeglogene autotemcel) for sickle cell disease. […]
Vicebio Announces $100 Million Series B Financing and Initiation of Phase 1 Clinical Study of RSV/hMPV Bivalent Vaccine Vicebio Ltd, a biopharmaceutical company developing novel vaccines against life-threatening respiratory viral infections, on Monday announced a $100 million Series B financing led by TCGX with investment from Goldman Sachs Alternatives, Avoro Ventures, venBio, and participation from UniQuest and founding investor Medicxi. London-based Vicebio said funding […]
